OptiNose (OPTN) Announced Proposed Stock Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 4% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Optinose Announces Proposed Public Offering of Common Stock and Warrants
November 21, 2022 6:12 AM ESTYARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to... More
